Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PBRM1 and BAP1 as novel targets for renal cell carcinoma.

Cancer journal (Sudbury, Mass.) - 1 Jan 2000

Brugarolas James

Abstract excerpt

Technological advances in genome sequencing have led to the identification of novel driver genes mutated in renal cancer. Hitherto, 1 gene was known to be frequently mutated in renal cell carcinoma of clear cell type (ccRCC), the von Hippel-Lindau (VHL) gene. VHL was identified by positional cloning as the gene responsible for a familial syndrome with renal cancer predisposition, von Hippel-Lindau. Subsequently,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Renal Cell
Share to Gene Expression Regulation, Neoplastic
Share to Kidney Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Targeted Therapy

Share to Nuclear Proteins

Share to Tumor Suppressor Proteins

Share to Ubiquitin Thiolesterase

Share to Von Hippel-Lindau Tumor Suppressor Protein

Source

Open in PubMed Open full text

Identifiers

PMID: 23867514
DOI: 10.1097/PPO.0b013e3182a102d1
PMCID: PMC4222578

Genes

VHL
BAP1
PBRM1
SETD2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PBRM1 and BAP1 as novel targets for renal cell carcinoma.PMID 23867514Read ↗

Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinomaSemantic proximity Read ↗

BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies.Semantic proximity Read ↗

Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma.Semantic proximity Read ↗

Epigenome Aberrations: Emerging Driving Factors of the Clear Cell Renal Cell Carcinoma.Semantic proximity Read ↗

Prognostic and Predictive Value of PBRM1 in Clear Cell Renal Cell CarcinomaSemantic proximity Read ↗

BAP1 loss defines a new class of renal cell carcinoma.Semantic proximity Read ↗

Molecular genetics of clear-cell renal cell carcinoma.Semantic proximity Read ↗

PBRM1, SETD2 and BAP1 - the trinity of 3p in clear cell renal cell carcinoma.Semantic proximity Read ↗

An integrative genomics approach for identifying novel functional consequences of PBRM1 truncated mutations in clear cell renal cell carcinoma (ccRCC).Semantic proximity Read ↗

Molecular aberrations, targeted therapy, and renal cell carcinoma: current state-of-the-art.Semantic proximity Read ↗

The epigenetic landscape of renal cancer.Semantic proximity Read ↗

Cooperation and antagonism among cancer genes: the renal cancer paradigm.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.